arrow
A

Aude G. Chapuis

Fred Hutchinson Cancer Center
H指数:30
被引数:4,720

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma

将工程化自体T细胞重编程以克服 Merkel细胞癌患者的耐药性

2026-09-090
PRE
Expert Panel Review and Practical Guidance on Biomarker Testing With Engineered Immune Effector Cells

专家小组评审及工程化免疫效应细胞生物标志物检测的实用指南

2026-05-160
OAAI
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles

推进实体瘤细胞疗法:克服生物学、操作和监管障碍的途径

2026-02-260
PRE
A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands

一种经过修饰以包含细胞内CD28信号尾部的CD8αβ共受体,能够独立于实体瘤相关共刺激配体而增强TCR工程化T细胞的功能。

2026-01-030
OA
Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models

胶原蛋白结合IL-12装甲STEAP1 CAR-T细胞可降低毒性并治疗小鼠模型中的前列腺癌

2025-10-230
OAAI
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials

Gamma-分泌酶抑制剂对BCMA CAR-T疗法后多发性骨髓瘤结局的影响:两项I期试验的比较

2025-09-080
PRE
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence
2025-06-050
OAAI
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

anti-PD-L1抗体起始时间影响CD19 car-t细胞治疗大b细胞淋巴瘤的疗效/毒性

2024-01-2311
OAAI
Preliminary safety results from a phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T cell receptor (TCR) (FH-TCR TMSLN) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDA)
2024-01-160
PRE
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19

重复的mRNA疫苗接种顺序地提高了具有先前新型冠状病毒肺炎的人的SARS-CoV-2-specific CD8 T细胞

2023-12-0610
OA
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

与CD19 CAR T细胞治疗复发/难治性CLL的长期结果相关的因素

2023-11-177
OAAI